ER and PR immunohistochemistry and HER2 FISH versus oncotype DX: Implications for breast cancer treatment

Breast Journal

Volumn 20, Issue 1, 2014, Pages 37-45

  Park, Mihee M ^a   Ebel, Joshua J ^a   Zhao, Weiquiang ^a   Zynger, Debra L ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

breast cancer; estrogen receptor; human epidermal growth factor; immunohistochemistry; oncotype DX; RT PCR

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; DIAGNOSTIC TEST; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MIDDLE AGED; ONCOTYPE DX; QUALITY CONTROL; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRIPLE NEGATIVE BREAST CANCER; VERY ELDERLY;

BREAST CANCER; ESTROGEN RECEPTOR; HUMAN EPIDERMAL GROWTH FACTOR; IMMUNOHISTOCHEMISTRY; ONCOTYPE DX; RT-PCR;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84892791786     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/tbj.12223     Document Type: Article

References (17)

1. American Cancer Society. Cancer Facts & Figures 2013. Available at: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/ document/acspc-036845.pdf (accessed March 20, 2013).
2. Hammond ME, Hayes DF, Dowsett M, et al,. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010; 28: 2784-95.
3. Wolff AC, Hammond ME, Schwartz JN, et al,. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007; 131: 18-43.
4. Paik S, Tang G, Shak S, et al,. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006; 24: 3726-34.
5. Paik S, Shak S, Tang G, et al,. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351: 2817-26.
6. United States Food and Drug Administration. Guidance for industry and FDA staff: Statistical guidance on reporting results from studies evaluating diagnostic tests. Available at: http://medical.cms.itri.org.tw/pdf/u14.pdf (accessed December 20, 2012).
7. O'Connor SM, Beriwal S, Dabbs DJ, Bhargava R,. Concordance between semiquantitative immunohistochemical assay and oncotype DX RT-PCR assay for estrogen and progesterone receptors. Appl Immunohistochem Mol Morphol 2010; 18: 268-72.
8. ®) qRT-PCR assay for estrogen and progesterone receptors: an independent quality assurance study. Mod Pathol 2012; 25: 869-76.
9. Badve SS, Baehner FL, Gray RP, et al,. Estrogen- and progesterone- receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J Clin Oncol 2008; 26: 2473-81.
10. Allison KH, Kandalaft PL, Sitlani CM, Dintzis SM, Gown AM,. Routine pathologic parameters can predict Oncotype DX recurrence scores in subsets of ER positive patients: who does not always need testing? Breast Cancer Res Treat 2012; 131: 413-24.
11. Dabbs DJ, Klein ME, Mohsin SK, Tubbs RR, Shuai Y, Bhargava R,. High false-negative rate of HER2 quantitative reverse transcription polymerase chain reaction of the Oncotype DX test: an independent quality assurance study. J Clin Oncol 2011; 29: 4279-85.
12. Baehner FL, Achacoso N, Maddala T, et al,. Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories. J Clin Oncol 2010; 28: 4300-6.
13. Dvorak L, Dolan M, Fink J, Varghese L, Henriksen J, Gulbahce HE,. Correlation between HER2 determined by fluorescence in situ hybridization and reverse transcription-polymerase chain reaction of the Oncotype DX test. Appl Immunohistochem Mol Morphol 2013; 21: 196-9.
14. ® Breast Cancer Assay Report Includes a Quantitative HER2 Score brochure. Available at: http://www.oncotypedx.com/en-US/Breast/HealthcareProfessionalsInvasive/Overview/ ~/media/157A0C5B39DD461F915CEA5CE05D5E27.ashx (accessed September 11, 2012).
15. Genomic Health. Quantitative Single Gene Scores. Available at: http://www.oncotypedx.com/en-US/Breast/HealthcareProfessionalsInvasive/Overview/ Scores (accessed September 11, 2012).
16. Acs G, Esposito NN, Kiluk J, Loftus L, Laronga C,. A mitotically active, cellular tumor stroma and/or inflammatory cells associated with tumor cells may contribute to intermediate or high Oncotype DX Recurrence Scores in low-grade invasive breast carcinomas. Mod Pathol 2012; 25: 556-66.
17. Baehner FL, Pomeroy C, Cherbavaz C, Shak S,. Biopsy cavities in breast cancer specimens: their impact on quantitative RT-PCR gene expression profiles and recurrence risk assessment. Mod Pathol 2009; 22 (1s): 28A-9A.